Image-01 (Dc751b37 3923 4431 8378 C818a1f87689 01)
Clarithromycin
Product Images NDC 68180-177
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Clarithromycin (NDC 68180-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image-02 (Dc751b37 3923 4431 8378 C818a1f87689 02)
This data presents the Mean Plasma Concentration of Clarithromycin Extended-Release Tablets at 24500 mg every 24 hours compared to Clarithromycin Tablets at 500 mg every 12 hours over a 24-hour period. The graph shows the concentration levels at different time points after dosing.*
Image02 (Dc751b37 3923 4431 8378 C818a1f87689 03)
This is a description of Clarithromycin extended-release tablets with a concentration of 500 mg per tablet. The usual dose is two tablets taken once daily with food. The tablets are film-coated and are to be stored at 25°C, with excursions permitted to 16°C to 30°C. The medication is manufactured by Lupin Pharmaceuticals for Lupin Limited and is available in bottles containing 60 tablets. The prescribing information should be consulted for complete dosing instructions.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
